Levels of B-type Natriuretic Peptide in Chronic Heart Failure Patients with and Without Diabetes Mellitus

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Dec 20

PMID 23251273

Citations 9

Authors

Qiang Peng

Weitong Hu

Hai Su

Qing Yang

Xiaoshu Cheng

Affiliations

Soon will be listed here.

Abstract

The current study aimed to observe the value of B-type natriuretic peptide (BNP) in chronic heart failure (CHF) patients with and without diabetes mellitus (DM). The study consisted of 559 CHF patients, including 276 patients with coronary heart disease, 234 with hypertensive heart disease and 49 with dilated cardiomyopathy. The subjects were divided into non-DM and DM groups which included 384 and 175 patients, respectively. Their New York Heart Association (NYHA) cardiac function degree and BNP levels were detected following admission. Other blood parameters, including fasting blood glucose and serum creatinine, were also collected. Left ventricular ejection fraction (LVEF) and the average thickness of the left ventricular wall (LVW) were detected by echocardiography. The total score of the heart failure (HF)-related parameters was evaluated for each patient according to age, hypertension, LVEF, LVW and NYHA degree. Additionally, BNP-score relation curves were constructed. The levels of BNP were significantly higher in the DM group compared with the non-DM group (1143.73±94.0 vs. 884.34±57.0 ng/l, P<0.05). Positive BNP-score relation curves were obtained for the DM and non-DM groups, but the curve of the DM group was notably steeper. As the patients with DM have significantly higher BNP levels at a similar HF score, DM history and fasting blood glucose should be taken into consideration when evaluating the value of BNP in HF.

Citing Articles

Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2-year adverse outcomes. Data from the FAR NHL registry.

Labr K, Spinar J, Parenica J, Spinarova L, Krejci J, Malek F J Diabetes. 2024; 16(9):e13605.

PMID: 39263998 PMC: 11391384. DOI: 10.1111/1753-0407.13605.

Prediction models for major adverse cardiovascular events following ST-segment elevation myocardial infarction and subgroup-specific performance.

Chen W, Tan X, Du X, Li Q, Yuan M, Ni H Front Cardiovasc Med. 2023; 10:1181424.

PMID: 37180806 PMC: 10167292. DOI: 10.3389/fcvm.2023.1181424.

Chronic Hyperglycaemia Inhibits Tricarboxylic Acid Cycle in Rat Cardiomyoblasts Overexpressing Glucose Transporter Type 4.

Stratmann B, Eggers B, Mattern Y, de Carvalho T, Marcus K, Tschoepe D Int J Mol Sci. 2022; 23(13).

PMID: 35806260 PMC: 9266806. DOI: 10.3390/ijms23137255.

Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.

Wolsk E, Claggett B, Diaz R, Dickstein K, Gerstein H, Kober L J Am Heart Assoc. 2022; 11(8):e021327.

PMID: 35383463 PMC: 9238457. DOI: 10.1161/JAHA.121.021327.

THE ROLE OF NT PRO-BNP IN THE EVALUATION OF DIABETIC PATIENTS WITH HEART FAILURE.

Fringu F, Sitar-Taut A, Caloian B, Zdrenghea D, Comsa D, Gusetu G Acta Endocrinol (Buchar). 2020; 16(2):183-191.

PMID: 33029235 PMC: 7535893. DOI: 10.4183/aeb.2020.183.

References

Boonman-de Winter L, Rutten F, Cramer M, Liem A, Landman M, van Stel H . Early recognition of heart failure in patients with diabetes type 2 in primary care. A prospective diagnostic efficiency study. (UHFO-DM2). BMC Public Health. 2009; 9:479. PMC: 2804618. DOI: 10.1186/1471-2458-9-479. View

Shen W . An intriguing association between congestive heart failure and diabetes mellitus. Chin Med J (Engl). 2010; 123(6):643-5. View

Palazzuoli A, Caputo M, Calabro A, Nuti R . Clinical impact of BNP and other emerging biomarkers in heart failure evaluation and management. Minerva Cardioangiol. 2012; 60(2):183-94. View

Yufu K, Takahashi N, Nakagawa M, Hara M, Saikawa T, Yoshimatsu H . Brain natriuretic peptide and cardiac autonomic function in type 2 diabetic patients. Diabetes Res Clin Pract. 2005; 72(1):12-9. DOI: 10.1016/j.diabres.2005.08.011. View

Marchant K . Diabetes and chronic kidney disease: a complex combination. Br J Nurs. 2008; 17(6):356-61. DOI: 10.12968/bjon.2008.17.6.28899. View

Siebenhofer A, Ng L, Plank J, Berghold A, Hodl R, Pieber T . Plasma N-terminal pro-brain natriuretic peptide in Type 1 diabetic patients with and without diabetic nephropathy. Diabet Med. 2003; 20(7):535-9. DOI: 10.1046/j.1464-5491.2003.00948.x. View

Beer S, Golay S, Bardy D, Feihl F, Gaillard R, Bachmann C . Increased plasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in type 2 diabetic patients with vascular complications. Diabetes Metab. 2005; 31(6):567-73. DOI: 10.1016/s1262-3636(07)70232-x. View

Dhingra R, Vasan R . Diabetes and the risk of heart failure. Heart Fail Clin. 2011; 8(1):125-33. PMC: 3223386. DOI: 10.1016/j.hfc.2011.08.008. View

Horwich T, Fonarow G . Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol. 2010; 55(4):283-93. PMC: 2834416. DOI: 10.1016/j.jacc.2009.07.029. View

10.

Kelder J, Cowie M, McDonagh T, Hardman S, Grobbee D, Cost B . Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011; 97(12):959-63. DOI: 10.1136/hrt.2010.220426. View

11.

Igarashi M, Jimbu Y, Hirata A, Tominaga M . Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes. Endocr J. 2005; 52(3):353-62. DOI: 10.1507/endocrj.52.353. View

12.

Aguiar V, Ochiai M, Cardoso J, Del Carlo C, Morgado P, Munhoz R . Relationship between depression, BNP levels and ventricular impairment in heart failure. Arq Bras Cardiol. 2010; 95(6):732-7. DOI: 10.1590/s0066-782x2010005000125. View

13.

van den Hurk K, Alssema M, Kamp O, Henry R, Stehouwer C, Diamant M . Slightly elevated B-type natriuretic peptide levels in a non-heart failure range indicate a worse left ventricular diastolic function in individuals with, as compared with individuals without, type 2 diabetes: the Hoorn Study. Eur J Heart Fail. 2010; 12(9):958-65. DOI: 10.1093/eurjhf/hfq119. View

14.

Liu C, Agnes G, Corcuff J, Bordenave L, Gin H, Rigalleau V . B-type natriuretic peptide in type 2 diabetes: the influence of chronic renal failure and food. Diabetes Care. 2005; 28(3):752. DOI: 10.2337/diacare.28.3.752. View

15.

Albertini J, Cohen R, Valensi P, Sachs R, Charniot J . B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients. Diabetes Metab. 2008; 34(4 Pt 1):355-62. DOI: 10.1016/j.diabet.2008.02.004. View

16.

Oremus M, Raina P, Santaguida P, Balion C, McQueen M, McKelvie R . A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. Clin Biochem. 2007; 41(4-5):260-5. DOI: 10.1016/j.clinbiochem.2007.09.011. View

17.

From A, Scott C, Chen H . The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010; 55(4):300-5. PMC: 3878075. DOI: 10.1016/j.jacc.2009.12.003. View

18.

Koitabashi T, Inomata T, Niwano S, Nishii M, Takeuchi I, Nakano H . Distinguishable optimal levels of plasma B-type natriuretic peptide in heart failure management based on complicated atrial fibrillation. Int Heart J. 2005; 46(3):453-64. DOI: 10.1536/ihj.46.453. View

19.

Chen H, Burnett J . Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000; 2(3):198-205. DOI: 10.1007/s11886-000-0069-3. View

20.

von Bibra H, St John Sutton M . Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Curr Heart Fail Rep. 2011; 8(4):242-51. PMC: 3208100. DOI: 10.1007/s11897-011-0070-8. View